Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT01962194
Other study ID # RE403-HMO-CTIL
Secondary ID
Status Not yet recruiting
Phase N/A
First received September 25, 2013
Last updated October 10, 2013
Start date December 2013
Est. completion date December 2015

Study information

Verified date June 2013
Source Hadassah Medical Organization
Contact Renana Eitan, MD
Email renanaeitan@gmail.com
Is FDA regulated No
Health authority Israel: Ethics Commission
Study type Interventional

Clinical Trial Summary

The investigators hypothesize that the emotional and cognitive areas of the Subthalamic Nucleus (STN) have distinct electrophysiological properties and that specific stimulation of these areas can influence the mental and the emotional state. Parkinson's disease (PD; n=5) and obsessive-compulsive disorder (OCD; n=5) patients that are candidates for treatment with Subthalamic Nucleus (STN) Deep Brain Stimulation (DBS) will be recruited over a period of two years. The patients will be enrolled in a prospective, open label, clinical trial and will be followed for one year. No randomization or blinding will be used in this study.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 10
Est. completion date December 2015
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender Both
Age group 20 Years to 75 Years
Eligibility Inclusion criteria of PD patients:

1. Patients with PD who meet accepted criteria for DBS surgery:

i. advanced idiopathic PD ii. long-term levodopa use that leads to decreased efficacy and increased incidence of adverse effects iii. normal cognitive function or mild-moderate cognitive decline (Addenbrooke's Cognitive Examination (ACE) > 75 and the Frontal Assessment Battery (FAB) > 10.

2. Age 40-75 years

3. Male or female

4. Competent and willing to give written informed consent

Exclusion Criteria of PD patients:

1. A diagnosis of severe major depression disorder (MDD) with psychotic features

2. Significant suicidal risk [Hamilton Depression scale item 3 (suicide) >2]

3. Lifetime history of substance or alcohol dependence or of abuse in the preceding 12 months

4. Significant cognitive decline, as measured by Addenbrooke's Cognitive Examination (ACE) < 75 and the Frontal Assessment Battery (FAB) < 10.

5. Significant cognitive impairment that would affect a participant's ability to give informed consent or provide interview or self-report data reliably

6. Any clinically significant abnormality on preoperative MRI

7. Any DBS contraindication, infection, coagulopathy, significant cardiac risk factors, or other medical risk factors for surgery

8. Pregnant and/or woman of childbearing age not using effective forms of birth control

Inclusion criteria of OCD patients:

1. Obsessive-compulsive disorder (OCD), diagnosed by Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (SCID-IV)

2. Presence of disabling severity, as assessed by a Yale-Brown Obsessive Compulsive Scale (YBOCS) score of at least 25

3. Documented highly treatment refractory OCD; the documentation must demonstrate persistence of severe symptoms and impairment for 5 or more years despite both pharmacological and psychological treatments.

4. Either drug free or on a stable drug regimen for at least 6 weeks before study entry

5. General good overall health

6. Age 20-70 years

7. Male or female

8. Competent and willing to give written informed consent.

Exclusion Criteria of OCD patients:

1. A diagnosis of severe major depression disorder (MDD) with psychotic features

2. Significant suicidal risk [Hamilton Depression scale item 3 (suicide) >2].

3. Comorbidity with any primary Psychotic Disorder, Bipolar Disorder, Post Traumatic Stress Disorder (PTSD), Eating Disorder.

4. Lifetime history of substance or alcohol dependence or of abuse in the preceding 12 months

5. Significant cognitive decline, as measured by Addenbrooke's Cognitive Examination (ACE) < 75 and the Frontal Assessment Battery (FAB) < 10.

6. Significant cognitive impairment that would affect a participant's ability to give informed consent or provide interview or self-report data reliably

7. Any another current clinically significant neurological disorder or medical illness affecting brain function, other than a tic disorder

8. Any clinically significant abnormality on preoperative MRI

9. Any DBS contraindication, infection, coagulopathy, significant cardiac risk factors, or other medical risk factors for surgery

10. Pregnant and/or woman of childbearing age not using effective forms of birth control

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Mapping the Limbic STN Using Neuronal Responses

Intervention

Device:
Deep Brain Stimulation
In this study we will use implantable Deep Brain Stimulation (DBS) system with local field potential sensing capability. The Device is the Medtronic, Inc DBS Implantable System, "Activa PC+S", which has therapy equivalent to "Activa PC", and has a new sensing programmer.

Locations

Country Name City State
Israel Hadassah Medical Center Jerusalem

Sponsors (1)

Lead Sponsor Collaborator
Hadassah Medical Organization

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mapping the limbic-associative STN in human using neuronal (single units & Local Field Potential (LFP)) responses to emotional stimuli during surgery and long term LFP recordings in PD and OCD patients Mapping the limbic-associative STN in human using neuronal (single units & Local Field Potential (LFP)) responses to emotional stimuli during surgery and long term LFP recordings in Parkinson's diseae (PD) and Obsessive Compulsive Disorder (OCD) patients two years No